Wealthfront’s PDL BioPharma, Inc. PDLI Stock Holding History

Wealthfront’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-76	Closed	–	–	1596
2015 Q2	$0	Buy	76 +65	+591%	+$435	﹤0.01%	1462
2015 Q1	$0	Buy	+11	New	+$80	﹤0.01%	1308

Other funds holding PDLI

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wealthfront's PDLI Position: Q3 2015 in Review

Wealthfront sold out of PDL BioPharma, Inc. (PDLI) in Q3 2015, closing a stake of 76 shares.

Wealthfront first reported a position in PDLI in Q1 2015 and held it in 2 quarters. The position peaked at $0 in Q2 2015. 213 funds tracked by Wall St. Rank hold PDLI as of Q3 2015.

Wealthfront reported no remaining PDL BioPharma, Inc. position as of Q3 2015 after selling out during the quarter.
Wealthfront sold 76 PDL BioPharma, Inc. shares in Q3 2015.
Wealthfront first reported a position in PDL BioPharma, Inc. in Q1 2015 and held it in 2 quarters.
Wealthfront's PDL BioPharma, Inc. position peaked at $0 in Q2 2015.
213 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2015.

Based on Wealthfront's 13F filing for Q3 2015, filed 18 Nov 2015.